Advertisement

Topics

Charles River Laboratories Announces Third-Quarter 2017 Results from Continuing Operations

07:00 EST 9 Nov 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
– Third-Quarter Revenue of $464.2 Million – – Third-Quarter GAAP EPS of $1.09 and Non-GAAP EPS of $1.30 – – Updates 2017 Guidance – Charles River Laboratories International, Inc. (NYSE: CRL) tod...

Other Sources for this Article

Charles River Laboratories International, Inc.
Investor Contact:
Susan E. Hardy, 781-222-6190
Corporate Vice President, Investor Relations
susan.hardy@crl.com
or
Media Contact:
Amy Cianciaruso, 781-222-6168
Corporate Vice President, Public Relations
amy.cianciaruso@crl.com

NEXT ARTICLE

More From BioPortfolio on "Charles River Laboratories Announces Third-Quarter 2017 Results from Continuing Operations"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Alliances, mergers acquisitions and partnerships
BioPortfolio's alliances, mergers acquisitions and partnerships channel provides the latest news and corporate information on the global bio-pharmaceutical industry.